News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […] December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Mind, Mood and Microbes: Harnessing the Power of Probiotics The canals of Amsterdam have attracted us this week to the capital of the Netherlands, where Winclove Probiotics has been working for more than 20 years in targeting the human microbiome. This field is now resurging, with research pointing to a close link between gut bacteria and human health. City: Amsterdam, the Netherlands Founded: 1991 Employees: 50+ Financial […] December 2, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Evotec gets hold of CRISPR in a new Partnership with Merck Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 7 European Institutions in the Largest Cancer Bioinformatics Collaboration Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […] December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 It’s World AIDS Day, is Biotech close to an HIV Cure? Biotech is working hard on developing an HIV cure, as well as fast diagnostics and vaccines. For those living with the disease, 2016 seems to be bringing new hope from the hands of science. Today, the 1st of December, is World AIDS Day. More than 36 million people live with HIV and 1 million died last year. The […] December 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 FDA and EMA review the First Therapy for a Deadly Skin Cancer Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […] November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 UPDATE: GSK is staging a comeback with a new Shingles Vaccine GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […] November 30, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 Drugging the Undruggable: New Acquisition to Boost GPCR Drugs Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […] November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 This was Labiotech Refresh! Check our recap and highlight video! Six months have passed since the last time we opened the doors for the very first Labiotech Refresh, Europe’s most refreshing Biotech Conference. Last week we launched our second edition live from Le Machine du Moulin Rouge in Paris! Were you not able to attend? Don’t worry! Here is our highlight video: And here’s also a […] November 30, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 Treating the Inner Ear: a solution for Vertigo is on the way! Sensorion is about to start Phase II trials to treat acute severe vertigo. What makes the inner ear such an attractive target for biotech? Sensorion is a French biotech developing treatments for inner ear pathologies, including vertigo, tinnitus and hearing loss. The company has just announced the start of Phase II trials with SENS-111, a drug candidate […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email